Neurelis Enters $208 Million Agreement to Monetize Intravail Royalties

San Diego, CA – November 14, 2024 – Neurelis, Inc. (“Company”), today announced a transaction with OrbiMed for the sale of the Company’s rights, royalty interests, and related sales milestone payments on global net sales of neffy® (nasal epinephrine) (the “Neffy Receivables”). Neurelis, through its subsidiary Aegis Therapeutics, LLC (“Aegis”), previously entered into an agreement […]

You are now leaving the Neurelis.com web site. Neurelis takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on third-party sites or servers.

Do you want to link to this third-party site and leave Neurelis.com?

You are now leaving the Neurelis.com web site. Neurelis takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on third-party sites or servers.

Do you want to link to this third-party site and leave Neurelis.com?

You are now leaving the Neurelis.com web site. Neurelis takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on third-party sites or servers.

Do you want to link to this third-party site and leave Neurelis.com?

You are now leaving the Neurelis.com web site. Neurelis takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on third-party sites or servers.

Do you want to link to this third-party site and leave Neurelis.com?

You are now leaving the Neurelis.com web site. Neurelis takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on third-party sites or servers.

Do you want to link to this third-party site and leave Neurelis.com?

You are now leaving the Neurelis.com web site. Neurelis takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on third-party sites or servers.

Do you want to link to this third-party site and leave Neurelis.com?

You are now leaving the Neurelis.com web site. Neurelis takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on third-party sites or servers.

Do you want to link to this third-party site and leave Neurelis.com?

You are now leaving the Neurelis.com web site. Neurelis takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on third-party sites or servers.

Do you want to link to this third-party site and leave Neurelis.com?

You are now leaving the Neurelis.com web site. Neurelis takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on third-party sites or servers.

Do you want to link to this third-party site and leave Neurelis.com?

You are now leaving the Neurelis.com web site. Neurelis takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on third-party sites or servers.

Do you want to link to this third-party site and leave Neurelis.com?

You are about to enter a site containing information on Medical Affairs and Research that is intended for US healthcare professionals only. Please confirm you are a healthcare professional and you wish to proceed to the HCP-only site.